Eli Lilly agreed to acquire Ventyx Biosciences in a roughly $1.2 billion all‑cash transaction, securing clinical‑stage NLRP3 inhibitor programs and near-term assets aimed at chronic inflammation. The deal consolidates Lilly’s access to oral NLRP3 inhibitors being tested across cardiometabolic, neurological and inflammatory indications. NLRP3 inhibitors block an intracellular inflammasome that drives chronic inflammation; the class is being explored for Alzheimer's, Parkinson’s, cardiovascular disease and autoimmune disorders. Lilly said it will fold Ventyx’s programs into its inflammation and neuroscience franchises and expects the transaction to close in the first half of 2026, subject to regulatory approvals and shareholder consent. Analysts flagged the acquisition as a strategic bolt‑on that accelerates Lilly’s oral‑small‑molecule exposure in immune modulation while complementing its obesity and metabolic portfolio.